Dr. Brian Bressler
Vancouver, British Columbia
5 Emerging Treatments
Discover the best doctors for your condition.
Learn about treatments beyond the ones offered by your doctor.
Crohn’s disease (CD) is a chronic inflammatory bowel disease characterized by diarrhea and
abdominal pain. Treatments include:
o 5-aminosalicylates, also known as 5-ASA (e.g. Asacol, Pentasa, Mezavant, Salofalk, and
o Steroids (e.g. Entocort, prednisone)
o Immunomodulators (e.g. Imuran, Purinethol, Rheumatrex)
o Biologics (e.g. Remicade, Humira, Entyvio)
5-ASAs are the most commonly prescribed drug class for CD however there is uncertainty regarding their effectiveness for treating CD. Despite this, doctors continue to prescribe a potentially ineffective treatment which, aside from costs ($23M in Canada/year), possibly delays the use of more effective treatments that could reduce the risk of preventable complications in patients, such as surgery.
The STATIC study is trying to determine if patients who stop taking their 5-ASA do no worse than those who continue taking their 5-ASA. Participants will be monitored for complications, surgeries or hospitalizations. The results of this study have potential to improve the lives of patients, change physician prescribing practice, and reduce health care costs.
This study is evaluating how safe and effective etrolizumab is compared to placebo for the treatment of moderate to severe Crohn's disease.
Vedolizumab is an intraveneous medication for ulcerative colitis who have had bowel surgery involving a proctocolectomy and ileal pouch anal anastomosis.
This study is evaluating how safe and effective etrolizumab is compared to placebo for the treatment of moderate to severe ulcerative colitis. Participants must have failed an anti-TNF therapy (e.g. Remicade, Humira, etc.) previously.